The J.P. Morgan Healthcare conference wrapped last week… but an analysis hangover has spilled into this week. Lord Voldemort of Harry Potter franchisedom is pictured above to denote Martin Shkreli, who could also be dubbed “He Who Must Not Be Named” at last week’s ‘do. Still: Shkreli has made several headlines this week, with both a Congressional subpoena to a FTC antitrust investigation – so that pseudonym isn’t exactly fitting these days.
Still, some of the top stories we wrote this week related to insights gleaned from the last, which you can see below:
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
1. Closing thoughts on the J.P. Morgan Healthcare Conference
Our livers rested, our business cards sheathed – one more year of the J.P. Morgan Healthcare Conference has come and gone. Given that the week was relatively quiet in terms of breaking news, the focus rested more solidly on trend analysis, moodiness – and what was not said. It also showed undercurrents of change.
2. 4 investors share insights on health tech from J.P. Morgan that will shape 2016
It looks like it will be a quiet year for health IT IPOs but convergence between life sciences and IT is gaining momentum, particularly as companies such as Proteus Digital Health partners begin to see health system partners make their technology available to patients.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
3. A startup CEO’s takeaways from J.P. Morgan and the hear ahead in digital health
Another JP Morgan annual healthcare conference has come and gone. I’ll share a few key takeaways – the first being that San Francisco is a nice break from chilly Boston this time of year. Coming out of JPM last week, I’ve been rethinking the year ahead and in this article I’ll highlight my key takeaways from the many meaningful discussions of the conference. In a second article later this week, I’ll offer some thoughts about what we expect to see in digital health in 2016 related to the job of healthcare providers and health plans.
4. Meaningful use is not dead: It’s reincarnated
Last week, CMS’s acting administrative director Andy Slavitt made an announcement that the Meaningful Use(MU) Program as we know it is effectively over.
Many people rejoiced at the “death” of MU. They failed to listen to all of his words.
He did not say that MU is dead. He said it is being replaced with something better.
5. NEJM: It’s time for ‘patient-driven health information economy’
After years and years of failure, the time may finally be right for personal health recordsand consumer control of medical data to catch on, two Harvard-affiliated informatics researchers said in a New England Journal of Medicine article published online late Wednesday afternoon. That can bring about “patient-controlled health-record infrastructure” to support a “patient-driven health information economy,” according to Dr. Kenneth Mandl, director of Boston Children’s Hospital’s Computational Health Informatics Program (CHIP), and Dr. Isaac Kohane, chair of the Department of Biomedical Informatics at Harvard Medical School.
